APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anticancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Anticancer Drugs Market Analysis and Forecast 2026-2032

23 December 2025202 pages

Choose your research edition.

Industry ResearchAnticancer Drugs Industry Research Report 2026140 pages · $2,950 USDIndustry Growth & TrendsGlobal Anticancer Drugs Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Anticancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anticancer Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Anticancer Drugs Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Anticancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Anticancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Anticancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Anticancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Anticancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Anticancer Drugs include Takeda, Johnson & Johnson, Novartis, Merck KGaA, Roche, Eli Lilly, Gilead Sciences, Pfizer and Hengrui Medicine, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Anticancer Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anticancer Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Anticancer Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anticancer Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anticancer Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Anticancer Drugs revenue, projected growth trends, production technology, application and end-user industry.

Anticancer Drugs Segment by Company

Takeda

Johnson & Johnson

Novartis

Merck KGaA

Roche

Eli Lilly

Gilead Sciences

Pfizer

Hengrui Medicine

GSK

Bristol-Myers Squibb

Amgen

AbbVie

AstraZeneca

Seagen

Regeneron

Ono Pharmaceutical

Merck & Co

Innovent

Exelixis

Anticancer Drugs Segment by Type

Cancer Immunotherapy

Chemotherapy

Targeted Therapy

Other

Anticancer Drugs Segment by Application

Blood-related Cancer

Breast Cancer

Prostate Cancer

Lung Cancer

Other

Anticancer Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anticancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anticancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anticancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Anticancer Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Anticancer Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anticancer Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anticancer Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cancer Immunotherapy Major Player Table 3. Chemotherapy Major Player Table 4. Targeted Therapy Major Player Table 5. Other Major Player Table 6. Global Anticancer Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Blood-related Cancer Major Player Table 8. Breast Cancer Major Player Table 9. Prostate Cancer Major Player Table 10. Lung Cancer Major Player Table 11. Other Major Player Table 12. Anticancer Drugs Industry Trends Table 13. Anticancer Drugs Industry Drivers Table 14. Anticancer Drugs Industry Opportunities and Challenges Table 15. Anticancer Drugs Industry Restraints Table 16. Global Anticancer Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Anticancer Drugs Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Anticancer Drugs Market Share by Region (2021-2026) Table 19. Global Anticancer Drugs Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Anticancer Drugs Market Share by Region (2027-2032) Table 21. Global Anticancer Drugs Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Anticancer Drugs Revenue Market Share by Players (2021-2026) Table 23. Global Anticancer Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Anticancer Drugs Key Players Headquarters & Area Served Table 25. Global Anticancer Drugs Players, Product Type & Application Table 26. Global Anticancer Drugs Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Anticancer Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Anticancer Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Anticancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Anticancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Anticancer Drugs Revenue Market Share by Type (2021-2026) Table 33. Global Anticancer Drugs Revenue Market Share by Type (2027-2032) Table 34. Global Anticancer Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Anticancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Anticancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Anticancer Drugs Revenue Market Share by Application (2021-2026) Table 38. Global Anticancer Drugs Revenue Market Share by Application (2027-2032) Table 39. Takeda Company Information Table 40. Takeda Business Overview Table 41. Takeda Anticancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Takeda Anticancer Drugs Product Portfolio Table 43. Takeda Recent Development Table 44. Johnson & Johnson Company Information Table 45. Johnson & Johnson Business Overview Table 46. Johnson & Johnson Anticancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Johnson & Johnson Anticancer Drugs Product Portfolio Table 48. Johnson & Johnson Recent Development Table 49. Novartis Company Information Table 50. Novartis Business Overview Table 51. Novartis Anticancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Novartis Anticancer Drugs Product Portfolio Table 53. Novartis Recent Development Table 54. Merck KGaA Company Information Table 55. Merck KGaA Business Overview Table 56. Merck KGaA Anticancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Merck KGaA Anticancer Drugs Product Portfolio Table 58. Merck KGaA Recent Development Table 59. Roche Company Information Table 60. Roche Business Overview Table 61. Roche Anticancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Roche Anticancer Drugs Product Portfolio Table 63. Roche Recent Development Table 64. Eli Lilly Company Information Table 65. Eli Lilly Business Overview Table 66. Eli Lilly Anticancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Eli Lilly Anticancer Drugs Product Portfolio Table 68. Eli Lilly Recent Development Table 69. Gilead Sciences Company Information Table 70. Gilead Sciences Business Overview Table 71. Gilead Sciences Anticancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Gilead Sciences Anticancer Drugs Product Portfolio Table 73. Gilead Sciences Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Anticancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Pfizer Anticancer Drugs Product Portfolio Table 78. Pfizer Recent Development Table 79. Hengrui Medicine Company Information Table 80. Hengrui Medicine Business Overview Table 81. Hengrui Medicine Anticancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Hengrui Medicine Anticancer Drugs Product Portfolio Table 83. Hengrui Medicine Recent Development Table 84. GSK Company Information Table 85. GSK Business Overview Table 86. GSK Anticancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. GSK Anticancer Drugs Product Portfolio Table 88. GSK Recent Development Table 89. Bristol-Myers Squibb Company Information Table 90. Bristol-Myers Squibb Business Overview Table 91. Bristol-Myers Squibb Anticancer Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Bristol-Myers Squibb Anticancer Drugs Product Portfolio Table 93. Bristol-Myers Squibb Recent Development Table 94. Amgen Company Information Table 95. Amgen Business Overview Table 96. Amgen Anticancer Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Amgen Anticancer Drugs Product Portfolio Table 98. Amgen Recent Development Table 99. AbbVie Company Information Table 100. AbbVie Business Overview Table 101. AbbVie Anticancer Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. AbbVie Anticancer Drugs Product Portfolio Table 103. AbbVie Recent Development Table 104. AstraZeneca Company Information Table 105. AstraZeneca Business Overview Table 106. AstraZeneca Anticancer Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. AstraZeneca Anticancer Drugs Product Portfolio Table 108. AstraZeneca Recent Development Table 109. Seagen Company Information Table 110. Seagen Business Overview Table 111. Seagen Anticancer Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Seagen Anticancer Drugs Product Portfolio Table 113. Seagen Recent Development Table 114. Regeneron Company Information Table 115. Regeneron Business Overview Table 116. Regeneron Anticancer Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. Regeneron Anticancer Drugs Product Portfolio Table 118. Regeneron Recent Development Table 119. Ono Pharmaceutical Company Information Table 120. Ono Pharmaceutical Business Overview Table 121. Ono Pharmaceutical Anticancer Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. Ono Pharmaceutical Anticancer Drugs Product Portfolio Table 123. Ono Pharmaceutical Recent Development Table 124. Merck & Co Company Information Table 125. Merck & Co Business Overview Table 126. Merck & Co Anticancer Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. Merck & Co Anticancer Drugs Product Portfolio Table 128. Merck & Co Recent Development Table 129. Innovent Company Information Table 130. Innovent Business Overview Table 131. Innovent Anticancer Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 132. Innovent Anticancer Drugs Product Portfolio Table 133. Innovent Recent Development Table 134. Exelixis Company Information Table 135. Exelixis Business Overview Table 136. Exelixis Anticancer Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 137. Exelixis Anticancer Drugs Product Portfolio Table 138. Exelixis Recent Development Table 139. North America Anticancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 140. North America Anticancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 141. North America Anticancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 142. North America Anticancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 143. North America Anticancer Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. North America Anticancer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 145. North America Anticancer Drugs Revenue by Country (US$ Million) & (2027-2032) Table 146. Europe Anticancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 147. Europe Anticancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 148. Europe Anticancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 149. Europe Anticancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 150. Europe Anticancer Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 151. Europe Anticancer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 152. Europe Anticancer Drugs Revenue by Country (US$ Million) & (2027-2032) Table 153. China Anticancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 154. China Anticancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 155. China Anticancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 156. China Anticancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 157. Asia Anticancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 158. Asia Anticancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 159. Asia Anticancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 160. Asia Anticancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 161. Asia Anticancer Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 162. Asia Anticancer Drugs Revenue by Region (US$ Million) & (2021-2026) Table 163. Asia Anticancer Drugs Revenue by Region (US$ Million) & (2027-2032) Table 164. SAMEA Anticancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 165. SAMEA Anticancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 166. SAMEA Anticancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 167. SAMEA Anticancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 168. SAMEA Anticancer Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 169. SAMEA Anticancer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 170. SAMEA Anticancer Drugs Revenue by Country (US$ Million) & (2027-2032) Table 171. Research Programs/Design for This Report Table 172. Authors List of This Report Table 173. Secondary Sources Table 174. Primary Sources List of Figures Figure 1. Anticancer Drugs Image Figure 2. Global Anticancer Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anticancer Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cancer Immunotherapy Image Figure 5. Chemotherapy Image Figure 6. Targeted Therapy Image Figure 7. Other Image Figure 8. Global Anticancer Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Anticancer Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Blood-related Cancer Image Figure 11. Breast Cancer Image Figure 12. Prostate Cancer Image Figure 13. Lung Cancer Image Figure 14. Other Image Figure 15. Global Anticancer Drugs Market Size (US$ Million) & (2021-2032) Figure 16. Global Anticancer Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Anticancer Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Anticancer Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Anticancer Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Anticancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Anticancer Drugs Revenue Market Share by Type (2021-2032) Figure 23. Global Anticancer Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Anticancer Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Anticancer Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Anticancer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Anticancer Drugs Revenue Share by Type (2021-2032) Figure 28. North America Anticancer Drugs Revenue Share by Application (2021-2032) Figure 29. North America Anticancer Drugs Revenue Share by Country (2021-2032) Figure 30. United States Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Anticancer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Anticancer Drugs Revenue Share by Type (2021-2032) Figure 35. Europe Anticancer Drugs Revenue Share by Application (2021-2032) Figure 36. Europe Anticancer Drugs Revenue Share by Country (2021-2032) Figure 37. Germany Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Anticancer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Anticancer Drugs Revenue Share by Type (2021-2032) Figure 47. China Anticancer Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Anticancer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Anticancer Drugs Revenue Share by Type (2021-2032) Figure 50. Asia Anticancer Drugs Revenue Share by Application (2021-2032) Figure 51. Asia Anticancer Drugs Revenue Share by Region (2021-2032) Figure 52. Japan Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Anticancer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Anticancer Drugs Revenue Share by Type (2021-2032) Figure 60. SAMEA Anticancer Drugs Revenue Share by Application (2021-2032) Figure 61. SAMEA Anticancer Drugs Revenue Share by Country (2021-2032) Figure 62. Brazil Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Anticancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Cancer Immunotherapy
  • Chemotherapy
  • Targeted Therapy
  • Other
Applications
  • Blood-related Cancer
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Other
Companies covered
  • Takeda
  • Johnson & Johnson
  • Novartis
  • Merck KGaA
  • Roche
  • Eli Lilly
  • Gilead Sciences
  • Pfizer
  • Hengrui Medicine
  • GSK
  • Bristol-Myers Squibb
  • Amgen
  • AbbVie
  • AstraZeneca
  • Seagen
  • Regeneron
  • Ono Pharmaceutical
  • Merck & Co
  • Innovent
  • Exelixis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anticancer Drugs Market by Type
  3. 1.2.1 Global Anticancer Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cancer Immunotherapy
  5. 1.2.3 Chemotherapy
  6. 1.2.4 Targeted Therapy
  7. 1.2.5 Other
  8. 1.3 Anticancer Drugs Market by Application
  9. 1.3.1 Global Anticancer Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Blood-related Cancer
  11. 1.3.3 Breast Cancer
  12. 1.3.4 Prostate Cancer
  13. 1.3.5 Lung Cancer
  14. 1.3.6 Other
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Anticancer Drugs Market Dynamics
  1. 2.1 Anticancer Drugs Industry Trends
  2. 2.2 Anticancer Drugs Industry Drivers
  3. 2.3 Anticancer Drugs Industry Opportunities and Challenges
  4. 2.4 Anticancer Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Anticancer Drugs Market Perspective (2021-2032)
  2. 3.2 Global Anticancer Drugs Growth Trends by Region
  3. 3.2.1 Global Anticancer Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anticancer Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Anticancer Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Anticancer Drugs Revenue by Players
  2. 4.1.1 Global Anticancer Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Anticancer Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Anticancer Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anticancer Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Anticancer Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Anticancer Drugs Players, Product Type & Application
  8. 4.5 Global Anticancer Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Anticancer Drugs Market CR5 and HHI
  11. 4.6.3 2025 Anticancer Drugs Tier 1, Tier 2, and Tier 3
5 Anticancer Drugs Market Size by Type
  1. 5.1 Global Anticancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Anticancer Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Anticancer Drugs Revenue Market Share by Type (2021-2032)
6 Anticancer Drugs Market Size by Application
  1. 6.1 Global Anticancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Anticancer Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Anticancer Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Anticancer Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Anticancer Drugs Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Anticancer Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Anticancer Drugs Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Anticancer Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Anticancer Drugs Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck KGaA
  20. 7.4.1 Merck KGaA Company Information
  21. 7.4.2 Merck KGaA Business Overview
  22. 7.4.3 Merck KGaA Anticancer Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck KGaA Anticancer Drugs Product Portfolio
  24. 7.4.5 Merck KGaA Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Anticancer Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche Anticancer Drugs Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Eli Lilly
  32. 7.6.1 Eli Lilly Company Information
  33. 7.6.2 Eli Lilly Business Overview
  34. 7.6.3 Eli Lilly Anticancer Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Eli Lilly Anticancer Drugs Product Portfolio
  36. 7.6.5 Eli Lilly Recent Developments
  37. 7.7 Gilead Sciences
  38. 7.7.1 Gilead Sciences Company Information
  39. 7.7.2 Gilead Sciences Business Overview
  40. 7.7.3 Gilead Sciences Anticancer Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Gilead Sciences Anticancer Drugs Product Portfolio
  42. 7.7.5 Gilead Sciences Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Anticancer Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Anticancer Drugs Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 Hengrui Medicine
  50. 7.9.1 Hengrui Medicine Company Information
  51. 7.9.2 Hengrui Medicine Business Overview
  52. 7.9.3 Hengrui Medicine Anticancer Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Hengrui Medicine Anticancer Drugs Product Portfolio
  54. 7.9.5 Hengrui Medicine Recent Developments
  55. 7.10 GSK
  56. 7.10.1 GSK Company Information
  57. 7.10.2 GSK Business Overview
  58. 7.10.3 GSK Anticancer Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 GSK Anticancer Drugs Product Portfolio
  60. 7.10.5 GSK Recent Developments
  61. 7.11 Bristol-Myers Squibb
  62. 7.11.1 Bristol-Myers Squibb Company Information
  63. 7.11.2 Bristol-Myers Squibb Business Overview
  64. 7.11.3 Bristol-Myers Squibb Anticancer Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Bristol-Myers Squibb Anticancer Drugs Product Portfolio
  66. 7.11.5 Bristol-Myers Squibb Recent Developments
  67. 7.12 Amgen
  68. 7.12.1 Amgen Company Information
  69. 7.12.2 Amgen Business Overview
  70. 7.12.3 Amgen Anticancer Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Amgen Anticancer Drugs Product Portfolio
  72. 7.12.5 Amgen Recent Developments
  73. 7.13 AbbVie
  74. 7.13.1 AbbVie Company Information
  75. 7.13.2 AbbVie Business Overview
  76. 7.13.3 AbbVie Anticancer Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 AbbVie Anticancer Drugs Product Portfolio
  78. 7.13.5 AbbVie Recent Developments
  79. 7.14 AstraZeneca
  80. 7.14.1 AstraZeneca Company Information
  81. 7.14.2 AstraZeneca Business Overview
  82. 7.14.3 AstraZeneca Anticancer Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 AstraZeneca Anticancer Drugs Product Portfolio
  84. 7.14.5 AstraZeneca Recent Developments
  85. 7.15 Seagen
  86. 7.15.1 Seagen Company Information
  87. 7.15.2 Seagen Business Overview
  88. 7.15.3 Seagen Anticancer Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Seagen Anticancer Drugs Product Portfolio
  90. 7.15.5 Seagen Recent Developments
  91. 7.16 Regeneron
  92. 7.16.1 Regeneron Company Information
  93. 7.16.2 Regeneron Business Overview
  94. 7.16.3 Regeneron Anticancer Drugs Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Regeneron Anticancer Drugs Product Portfolio
  96. 7.16.5 Regeneron Recent Developments
  97. 7.17 Ono Pharmaceutical
  98. 7.17.1 Ono Pharmaceutical Company Information
  99. 7.17.2 Ono Pharmaceutical Business Overview
  100. 7.17.3 Ono Pharmaceutical Anticancer Drugs Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Ono Pharmaceutical Anticancer Drugs Product Portfolio
  102. 7.17.5 Ono Pharmaceutical Recent Developments
  103. 7.18 Merck & Co
  104. 7.18.1 Merck & Co Company Information
  105. 7.18.2 Merck & Co Business Overview
  106. 7.18.3 Merck & Co Anticancer Drugs Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Merck & Co Anticancer Drugs Product Portfolio
  108. 7.18.5 Merck & Co Recent Developments
  109. 7.19 Innovent
  110. 7.19.1 Innovent Company Information
  111. 7.19.2 Innovent Business Overview
  112. 7.19.3 Innovent Anticancer Drugs Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Innovent Anticancer Drugs Product Portfolio
  114. 7.19.5 Innovent Recent Developments
  115. 7.20 Exelixis
  116. 7.20.1 Exelixis Company Information
  117. 7.20.2 Exelixis Business Overview
  118. 7.20.3 Exelixis Anticancer Drugs Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Exelixis Anticancer Drugs Product Portfolio
  120. 7.20.5 Exelixis Recent Developments
8 North America
  1. 8.1 North America Anticancer Drugs Revenue (2021-2032)
  2. 8.2 North America Anticancer Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Anticancer Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Anticancer Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Anticancer Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Anticancer Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Anticancer Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Anticancer Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Anticancer Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Anticancer Drugs Revenue by Country
  11. 8.6.1 North America Anticancer Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Anticancer Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Anticancer Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Anticancer Drugs Revenue (2021-2032)
  2. 9.2 Europe Anticancer Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Anticancer Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Anticancer Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Anticancer Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Anticancer Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Anticancer Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Anticancer Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Anticancer Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Anticancer Drugs Revenue by Country
  11. 9.6.1 Europe Anticancer Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Anticancer Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Anticancer Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Anticancer Drugs Revenue (2021-2032)
  2. 10.2 China Anticancer Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Anticancer Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Anticancer Drugs Revenue by Type (2027-2032)
  5. 10.3 China Anticancer Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Anticancer Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Anticancer Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Anticancer Drugs Revenue by Application (2027-2032)
  9. 10.5 China Anticancer Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anticancer Drugs Revenue (2021-2032)
  2. 11.2 Asia Anticancer Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Anticancer Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Anticancer Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Anticancer Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Anticancer Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Anticancer Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Anticancer Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Anticancer Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Anticancer Drugs Revenue by Country
  11. 11.6.1 Asia Anticancer Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Anticancer Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Anticancer Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anticancer Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Anticancer Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Anticancer Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Anticancer Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Anticancer Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Anticancer Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Anticancer Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Anticancer Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Anticancer Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Anticancer Drugs Revenue by Country
  11. 12.6.1 SAMEA Anticancer Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Anticancer Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Anticancer Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst